These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10619519)

  • 41. Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery.
    Thomas DC; Arnold BN; Rosen JE; Salazar MC; Blasberg JD; Detterbeck FC; Boffa DJ; Kim AW
    Lung Cancer; 2017 Jan; 103():75-81. PubMed ID: 28024700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Is surgery indicated for stage IIIA-N2 non-small-cell lung cancer?].
    Gounant V; Lavolé A; Epaud C; Rosencher L; Milleron B
    Rev Pneumol Clin; 2007 Jun; 63(3):135-7. PubMed ID: 17675936
    [No Abstract]   [Full Text] [Related]  

  • 43. [Early stages of non small cell lung cancer (I. II. IIIA). What is the best therapeutic strategy?].
    Riquet M; Berna P
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S36-16S42. PubMed ID: 17268334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of predictive factors for postoperative survival for non small cell lung carcinoma patients with unexpected mediastinal lymph nodes metastasis.
    Wang S; Zhou W; Zhang H; Zhao M; Chen X
    Thorac Cardiovasc Surg; 2014 Mar; 62(2):126-32. PubMed ID: 23585223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of chemotherapy in stages I to III non-small cell lung cancer.
    Strauss GM
    Chest; 1999 Dec; 116(6 Suppl):509S-516S. PubMed ID: 10619521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pre- and intra-operative mediastinal staging in non-small-cell lung cancer.
    Lardinois D
    Swiss Med Wkly; 2011; 141():w13168. PubMed ID: 21384283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival.
    Cerfolio RJ; Bryant AS; Jones VL; Cerfolio RM
    Eur J Cardiothorac Surg; 2009 Apr; 35(4):718-23; discussion 723. PubMed ID: 19233668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Impact of the number of resected and involved lymph nodes on the outcome in patients with stage II non-small cell lung cancer].
    Dai Y; Long H; Lin P; Fu JH; Zhang LJ; Zhu ZH; Zhang X; Rong TH; Su XD
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):436-40. PubMed ID: 20819485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer.
    Inoue M; Maeda H; Takeuchi Y; Fukuhara K; Shintani Y; Funakoshi Y; Funaki S; Nojiri T; Kusu T; Kusumoto H; Kimura T; Okumura M;
    Surg Today; 2018 Apr; 48(4):380-387. PubMed ID: 28993901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of complete lymph node dissection for lung cancer on the postoperative course.
    Date H
    Thorac Surg Clin; 2012 May; 22(2):239-42. PubMed ID: 22520291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Postoperative adjuvant therapy in combined lung cancer treatment].
    Cicenas S; Piscikas DA; Jakubauskiene R
    Medicina (Kaunas); 2004; 40 Suppl 1():156-60. PubMed ID: 15079128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intraoperative staging and surgical management of stage IIIA/N2 non-small cell lung cancer.
    Brichkov I; Keller SM
    Thorac Surg Clin; 2008 Nov; 18(4):381-91. PubMed ID: 19086607
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Impact of TNM staging and treatment mode on the prognosis of non-small cell lung cancer].
    Yu DP; Bai LQ; Xu SF; Han M; Wang ZT
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):465-8. PubMed ID: 19950561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The role of adjuvant therapy in the management of pN2 non-small-cell carcinoma of the lung].
    Chella A; Lucchi M; Gragnani F; Ribechini A; Silvano G; Janni A; Mussi A; Angeletti CA
    Minerva Chir; 1995 Dec; 50(12):1029-38. PubMed ID: 8725059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Management of resectable non-small cell lung cancer. Guidelines of clinical practice made by the European Lung Cancer Working Party].
    Sculier JP;
    Rev Med Brux; 2014; 35(3):134-9. PubMed ID: 25102579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival following resection of clinically occult N2 non small cell lung cancer.
    Dalton R; Keller S
    J Cardiovasc Surg (Torino); 1994 Dec; 35(6 Suppl 1):13-7. PubMed ID: 7775526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
    J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The controversial role of surgery in stage III NSCLC.
    van Meerbeeck JP
    Lancet Oncol; 2008 Jul; 9(7):607-8. PubMed ID: 18598926
    [No Abstract]   [Full Text] [Related]  

  • 59. Subcarinal Lymph Nodes Should be Dissected in All Lobectomies for Non-Small Cell Lung Cancer-Regardless of Primary Tumor Location.
    Eckardt J; Jakobsen E; Licht PB
    Ann Thorac Surg; 2017 Apr; 103(4):1121-1125. PubMed ID: 28109572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Surgery: therapeutic indications.
    Van Schil PE
    Cancer Radiother; 2007; 11(1-2):47-52. PubMed ID: 16837227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.